[
  {
    "ts": null,
    "headline": "Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD. This regulatory milestone is the second t",
    "url": "https://finnhub.io/api/news?id=154fb2cfc503872fb00cf32dca16bd8b99eb6dd0398fa7e529be206fb3efdcba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731359100,
      "headline": "Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease",
      "id": 131293853,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD. This regulatory milestone is the second t",
      "url": "https://finnhub.io/api/news?id=154fb2cfc503872fb00cf32dca16bd8b99eb6dd0398fa7e529be206fb3efdcba"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=106011d1349d7c0fdae57386f385558f8594053977db1090e414bc41e09dac74",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342660,
      "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "id": 131413915,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=106011d1349d7c0fdae57386f385558f8594053977db1090e414bc41e09dac74"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?",
    "summary": "It is hard to get excited after looking at Johnson & Johnson's (NYSE:JNJ) recent performance, when its stock has...",
    "url": "https://finnhub.io/api/news?id=6757b84e61924e53017da22a0cd85ff33c25df5033b1a8d9e7ca9b994e579c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731322881,
      "headline": "Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?",
      "id": 131285620,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "It is hard to get excited after looking at Johnson & Johnson's (NYSE:JNJ) recent performance, when its stock has...",
      "url": "https://finnhub.io/api/news?id=6757b84e61924e53017da22a0cd85ff33c25df5033b1a8d9e7ca9b994e579c96"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO, DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma",
    "summary": "RARITAN - Johnson & Johnson today announced the submission of regulatory applications to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of a new indication for...",
    "url": "https://finnhub.io/api/news?id=d6be0ed277c034b09d86283e37c206eb347fbeacb040033c4f79f43a928cdff0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731321386,
      "headline": "Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO, DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma",
      "id": 131285651,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "RARITAN - Johnson & Johnson today announced the submission of regulatory applications to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of a new indication for...",
      "url": "https://finnhub.io/api/news?id=d6be0ed277c034b09d86283e37c206eb347fbeacb040033c4f79f43a928cdff0"
    }
  },
  {
    "ts": null,
    "headline": "Spravato is just the beginning in a new wave of depression meds",
    "summary": "Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.",
    "url": "https://finnhub.io/api/news?id=28ee56eba421e7b00f016915e177c9040feed05d1a4998ed0b5104292a017d8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731312000,
      "headline": "Spravato is just the beginning in a new wave of depression meds",
      "id": 131285622,
      "image": "https://imgproxy.divecdn.com/03RRjDr_GK6lb4luigVJcLO-jNm2Xo1D_Xfdpl-8Bz4/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTA5MjY3MzY3LmpwZw==.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.",
      "url": "https://finnhub.io/api/news?id=28ee56eba421e7b00f016915e177c9040feed05d1a4998ed0b5104292a017d8e"
    }
  }
]